zolbetuximab zolbetuximab zolbetuximab (development code imab362) is an experimental monoclonal antibody against isoform 2 of claudin-18. it is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. imab362 was developed by ganymed pharmaceuticals ag. astellas pharmaceuticals acquired the rights to zolbetuximab in december, 2016 when it acquired ganymed pharmaceuticals. zolbetuximabmonoclonal antibodytypewhole antibodysourcechimerictargetcldn18.2clinical dataother namesimab362; claudiximabatc codenonelegal statuslegal status investigational identifierscas number1496553-00-4chemspidernoneuniitf5mpq8wgy ny (what is this?) (verify) the drug was in phase iii clinical trials as of november 2021 for gastric cancer.